Chronic kidney disease is one of the most common long-term complications of type 2 diabetes. The kidneys filter blood constantly, and years of elevated blood sugar can gradually damage the tiny vessels that make that filtration possible. Once kidney function declines far enough, a person may need dialysis or a transplant, so researchers are keenly interested in any treatment that might slow that progression.
A class of compounds called GLP-1 receptor agonists has attracted significant attention in this area. These peptides mimic a naturally occurring gut hormone, glucagon-like peptide-1, that helps regulate blood sugar. Earlier research had already shown that GLP-1 receptor agonists as a group are linked to better kidney outcomes than older diabetes drug classes. What was less clear was whether individual members of that group performed differently from one another.
A recent study published in a major nephrology journal tackled exactly that question, comparing four GLP-1 receptor agonists, dulaglutide, exenatide, liraglutide, and semaglutide, in a large, real-world dataset of adults with type 2 diabetes and moderate cardiovascular risk.
Study design and data source
The research team used a method called target trial emulation, which is a framework for analyzing observational data in a way that closely mirrors how a randomized controlled trial would be structured. Rather than randomly assigning participants to treatments in advance, the researchers used statistical tools to mimic that process after the fact.
The data came from two large sources: a commercial insurance claims warehouse and the complete Medicare fee-for-service claims database. Participants were adults aged 21 or older who filled a new prescription for one of the four GLP-1 receptor agonists between January 2019 and December 2021. All participants had type 2 diabetes and were classified as being at moderate cardiovascular risk.
To account for the fact that doctors may prescribe different drugs to different types of patients, the researchers used a technique called inverse probability of treatment weighting. This approach assigns statistical weights to participants so that the groups being compared look more similar on paper, reducing the chance that a difference in outcomes is actually explained by a difference in who received which drug.
What the researchers measured
The primary outcome was a composite measure of kidney events, specifically new diagnoses of chronic kidney disease at stages 3 or 4, kidney failure, or the need for kidney replacement therapy such as dialysis or transplant.
A secondary outcome added all-cause death to that composite. The researchers also looked at each component of both composites individually, so they could see whether any differences were driven by a specific event type rather than the combined measure.
Time-to-event modeling was used, meaning the analysis tracked how long it took for an outcome to occur rather than simply counting who experienced one. This approach is better suited to capturing differences that emerge gradually over a follow-up period.
Key findings on kidney progression
For the primary kidney composite outcome, the study found no statistically meaningful difference among the four GLP-1 receptor agonists. In other words, when looking only at diagnosed kidney disease progression and kidney failure, dulaglutide, exenatide, liraglutide, and semaglutide performed similarly.
The picture changed when death was added to the composite to form the secondary outcome. Semaglutide was associated with an 8 percent lower risk of reaching the secondary composite compared to dulaglutide, with a hazard ratio of 0.92 and a 95 percent confidence interval of 0.87 to 0.97. Compared to exenatide, that relative risk reduction was 12 percent, with a hazard ratio of 0.88 and a confidence interval of 0.79 to 0.99.
Looking at death alone, semaglutide was associated with a 19 percent lower risk compared to dulaglutide, with a hazard ratio of 0.81 and a 95 percent confidence interval of 0.70 to 0.93. The authors noted that this mortality difference appears to be a meaningful driver of the secondary composite result.
Limitations the authors acknowledged
The researchers were transparent about several important caveats. Because this was a retrospective study using insurance claims, there was potential for residual confounding. That means unmeasured factors, things the claims data simply do not capture, could still be influencing which patients ended up on which drug and how they fared.
The dataset lacked information on HbA1c, a standard marker of long-term blood sugar control, as well as body weight. Both of those variables are clinically relevant when studying kidney outcomes in diabetes, and their absence limits how confidently any differences can be attributed to the drugs themselves.
There was also uncertainty about why each prescription was written. Doctors may have had reasons for choosing one GLP-1 receptor agonist over another that were not captured in the claims data, and those reasons could be connected to how patients ultimately did.
Mechanistic context from the literature
The literature suggests that GLP-1 receptor agonists may support kidney health through several pathways beyond blood sugar lowering. Researchers have pointed to reductions in inflammation, improvements in blood pressure, and effects on the filtration pressure within the kidney's tiny vessels as possible contributors. Whether those mechanisms differ meaningfully across individual GLP-1 peptides is an area of ongoing investigation.
Semaglutide, the compound that showed the most favorable secondary outcome profile in this analysis, has a longer half-life than some of its predecessors in the class. Early data points at structural differences among GLP-1 receptor agonists influencing how strongly they bind to the receptor and how long that activation lasts, which may translate into different downstream effects. However, the current study was not designed to isolate any single mechanism, so those explanations remain speculative.
The authors concluded that their findings suggest semaglutide may represent a preferred option within the GLP-1 receptor agonist class for reducing the combined risk of kidney disease progression and death in people with type 2 diabetes at moderate cardiovascular risk. They called for prospective, randomized head-to-head trials to confirm these observations with stronger causal evidence.
Broader significance for peptide research
This study adds to a growing body of work exploring whether members of the same peptide class can have meaningfully different effects even when their shared mechanism of action might suggest they would behave similarly. The findings reinforce the idea that molecular differences in half-life, receptor binding affinity, and dosing frequency may translate into measurable differences in real-world outcomes.
For researchers and clinicians tracking the GLP-1 receptor agonist literature, the takeaway is nuanced. The four compounds studied appear largely equivalent on structural kidney disease progression when death is not part of the picture, but semaglutide's apparent edge on mortality is enough to shift the combined outcome. Future prospective trials with access to laboratory data on kidney function, blood sugar control, and body weight will be needed to determine whether this signal holds up under more controlled conditions.
